The protective effects of liguzinediol on congestive heart failure induced by myocardial infarction and its relative mechanism

Figures

• 

  Fig. 1. The chemical structure of liguzinediol

• 

  Fig. 2. Effects of liguzinediol on of myocardial tissue in MI rats. a The morphology of myocardial tissue was stained by H&E (×200). b The ultrastructure of myocardial tissue was observed by transmission electron microscopy (×8000)

• 

  Fig. 3. Effects of liguzinediol on extracellular matrix remodeling in MI rats. a The deposition of collagen fibers was stained by Masson (×200). b The level of HYP in myocardial tissue was detected by kits (n = 10). c The levels of collagen I and III in serum were detected by Elisa kits (n = 10). d The expressions of MMP2, MMP9 and TIMP1 in myocardial tissue were detected by western blot (n = 3). Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, compared to Sham group; #P < 0.05, ##P < 0.01, compared to MI group

• 

  Fig. 4. Effects of liguzinediol on RAAS, inflammation and oxidative stress in MI rats. a–c The levels of AngII, ALD and PRA in serum. d–f The levels of pro-inflammation factors IL-1β, IL-6 and TNF-α in serum. g, h The levels of MDA and SOD in LV. Data are shown as the mean ± SD (n = 10). *P < 0.05, **P < 0.01, compared to Sham group; #P < 0.05, ##P < 0.01, compared to MI group

• 

  Fig. 5. Effects of liguzinediol on TGF-β1/Smads pathway in MI rats. a The level of TGF-β in serum was detected by Elisa kit (n = 10). b Relative mRNA expressions of TGF-β1, Smad2, Smad3, Smad7 and CD105 in LV were detected by RT-PCR (n = 3). c Relative protein expressions of TGF-β1, Smad2, p-Smad2, Smad3, p-Smad3, Smad7 and CD105 in LV were detected by western blot (n = 3). Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, compared to Sham group; #P < 0.05, ##P < 0.01, compared to MI group